Inovio Pharmaceuticals
126 hedge funds and large institutions have $142M invested in Inovio Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 18 closing their positions.
20% more capital invested
Capital invested by funds: $118M → $142M (+$23.5M)
8% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 37
0.13% more ownership
Funds ownership: 2.64% → 2.77% (+0.13%)
5% less funds holding
Funds holding: 133 → 126 (-7)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
21% less call options, than puts
Call options by funds: $479K | Put options by funds: $603K
Top Buyers
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$2.28M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.09M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.71M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.22M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$767K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.15M |
| 2 |
BlackRock
New York
|
-$624K |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$579K |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$456K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$434K |
INO Hedge Fund Activity: Q1 2018 in Review
126 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2018, worth a combined $142M — up 20% from $118M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of INO and 15 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 40 added.
The largest buyer was Guggenheim Capital, opening a new position worth an estimated $2.28M. The largest seller was Citadel Advisors, cutting an estimated $1.15M.
- 126 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2018, down from 133 in Q4 2017.
- Funds reported $142M of Inovio Pharmaceuticals stock for Q1 2018, up 20% quarter-over-quarter.
- 15 funds opened new Inovio Pharmaceuticals positions in Q1 2018 and 18 closed out, a net change of -3 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2018 was Guggenheim Capital, an estimated $2.28M added.
- The largest Inovio Pharmaceuticals seller in Q1 2018 was Citadel Advisors, an estimated $1.15M sold.
Based on aggregated 13F filings for Q1 2018.